The summer months at the United States Food and Drug Administration are typically among the busiest on the regulatory calendar, and 2026 is proving no exception. With a succession of high-profile FDA drug approval decisions concentrated in June and July 2026, the agency is navigating a critical period of clinical progress alongside significant internal upheaval. The departure of Commissioner Marty Makary in May 2026 and the appointment of Acting Commissioner Kyle Diamantas have introduced fresh questions about continuity and regulatory philosophy at an agency that was already under intense scrutiny.
A Turbulent Backdrop
Makary’s exit on 12 May 2026, after just over a year in the role, capped a period of significant disruption at the FDA. Mass layoffs, senior departures, and a series of controversial regulatory decisions during his tenure drew sustained criticism from pharma executives, physicians, and patient advocates. Kyle Diamantas, a Florida attorney and former deputy commissioner for food, took over in an acting capacity and has moved quickly to signal a shift in tone, pledging at a rare disease stakeholder meeting in late May that he would act to prevent political interference in regulatory reviews.
That reassurance matters, because the June and July 2026 PDUFA window is substantial, spanning approvals already delivered and decisions still outstanding across oncology, virology, nephrology, and immunology. Those following the broader context of Trump-era FDA policy shifts will recognise the backdrop against which these decisions are being made.
Datroway Approved for Triple-Negative Breast Cancer
One of the most significant FDA drug approval decisions in this window came on 22 May 2026, when the FDA granted full approval to datopotamab deruxtecan (Datroway; Daiichi Sankyo and AstraZeneca) for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor therapy.
The decision was based on results from the Phase 3 TROPION-Breast02 trial, which enrolled 644 patients and compared the TROP2-directed antibody-drug conjugate against investigator’s choice of chemotherapy in the first-line setting. Datroway met both co-primary endpoints, extending median overall survival by five months and nearly doubling median progression-free survival. Confirmed objective response rate was 64%, with 9% of patients achieving complete response. The review was conducted under Project Orbis, the FDA’s framework for concurrent international oncology review, alongside partner agencies from Australia, Brazil, Canada, Singapore, and Switzerland.
The approval represents an important new option in a subtype historically characterised by poor prognosis and limited choices for patients ineligible for immunotherapy. Datroway had previously received approval in January 2025 for HR-positive, HER2-negative metastatic breast cancer, making this its second breast cancer indication.
Ensitrelvir: The First Oral COVID-19 Post-Exposure Prophylactic
On 1 June 2026, the FDA approved ensitrelvir (Xocova; Shionogi) ahead of its 16 June 2026 PDUFA date, making it the first oral antiviral approved to prevent COVID-19 following exposure to an infected individual. The approval covers adults and adolescents aged 12 years and older. The approval is supported by data from the Phase 3 SCORPIO-PEP trial, the only Phase 3 study of an oral antiviral to meet its primary endpoint in this setting. Ensitrelvir reduced the risk of symptomatic COVID-19 by 67% through Day 10 compared with placebo, in participants exposed to an infected household member. The drug is administered as a five-day oral regimen, with three tablets on Day 1 and one tablet on each of Days 2 through 5. Adverse event rates were broadly comparable to placebo.
Atacicept for IgA Nephropathy: PDUFA 7 July 2026
Among the most closely watched remaining FDA drug approval decisions in July 2026 is atacicept (Vera Therapeutics), a recombinant fusion protein targeting both BAFF and APRIL, two cytokines central to the pathogenesis of immunoglobulin A nephropathy (IgAN). The PDUFA target action date is 7 July 2026.
Vera has filed for accelerated approval based on data from the ORIGIN programme. Phase 3 results from the ORIGIN 3 trial, presented at the American Society of Nephrology Kidney Week in November 2025 and simultaneously published in The New England Journal of Medicine, showed a 46% reduction from baseline in proteinuria and a statistically significant 42% reduction compared to placebo. Secondary endpoints also favoured atacicept, including a 68% reduction in Gd-IgA1 and resolution of haematuria in 81% of participants who had haematuria at baseline.
If approved, atacicept would be the first therapy targeting both BAFF and APRIL in IgAN, offering a differentiated mechanism relative to currently available treatments. The drug would be self-administered at home via a once-weekly subcutaneous injection. In June 2026, Vera announced alignment with the FDA on an accelerated eGFR analysis from ORIGIN 3, now expected in Q3 2026, with full approval potentially following in 2027 via a supplemental BLA.
Gedatolisib for Advanced Breast Cancer: PDUFA 17 July 2026
Arguably the most clinically significant oncology FDA drug approval decision expected in July 2026 is the verdict on gedatolisib (Celcuity), with a PDUFA target action date of 17 July 2026. It is a first-in-class, multitarget inhibitor of the PI3K/AKT/mTOR pathway, filed under priority review for HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer in patients who have progressed after CDK4/6 inhibitor and aromatase inhibitor therapy.
The NDA was submitted under the FDA’s Real-Time Oncology Review programme, and gedatolisib previously received both Breakthrough Therapy and Fast Track designations. The application is grounded in pivotal Phase 3 results from the VIKTORIA-1 trial, presented at the ESMO Congress in October 2025 and published in the Journal of Clinical Oncology.
VIKTORIA-1 enrolled 392 patients with PIK3CA wild-type disease. The gedatolisib triplet, combining gedatolisib with palbociclib and fulvestrant, achieved a median progression-free survival of 9.3 months versus 2.0 months for fulvestrant alone, representing a 76% reduction in the risk of disease progression or death. The doublet of gedatolisib and fulvestrant achieved 7.4 months median PFS, a 67% risk reduction. Objective response rates were 31.5% for the triplet and 28.3% for the doublet, compared with 1% in the control arm.
Sara Hurvitz, MD, Senior Vice President of the Clinical Research Division at Fred Hutchinson Cancer Center and co-principal investigator for the trial, noted that to her knowledge no Phase 3 results in HR-positive, HER2-negative advanced breast cancer had previously shown a quadrupling in the likelihood of survival without disease progression relative to the study control.
If granted, approval would address a specific unmet need in patients with PIK3CA wild-type status, for whom existing single-isoform PI3K inhibitors offer no benefit.
Brepocitinib for Dermatomyositis: Third Quarter Target
Also anticipated in the third quarter of 2026 is brepocitinib (Priovant Therapeutics), a TYK2/JAK1 inhibitor under priority review for the treatment of dermatomyositis. The Phase 3 VALOR trial enrolled 241 patients and met its primary endpoint, with brepocitinib 30mg achieving a 15.3-point greater improvement in mean Total Improvement Score at Week 52 versus placebo (p<0.001), with benefits observed as early as Week 4. All nine key secondary endpoints were also met. Notably, 62% of brepocitinib-treated patients on background steroids were able to taper to ≤2.5mg/day by Week 52, compared with 34% on placebo. Full trial results were published in the New England Journal of Medicine in March 2026. If approved, brepocitinib would be the first targeted therapy approved for dermatomyositis, a rare and debilitating inflammatory muscle disease with no approved targeted treatment.
Leadership Transition and Implications for the Pipeline
The question of whether the FDA’s leadership churn will affect the pace or predictability of the FDA drug approval decisions falling in June and July 2026 remains an open one. Acting Commissioner Diamantas has moved to restore institutional confidence, appointing new acting directors across the Centre for Drug Evaluation and Research and the Centre for Biologics Evaluation and Research following the simultaneous departure of several senior officials in mid-May. Regulatory professionals and patient advocates have noted cautious optimism about his stated commitment to scientific integrity, although the full effects of months of leadership instability on review timelines are not yet fully understood.
For sponsors and investors, the verdicts on gedatolisib and atacicept in early-to-mid July carry the greatest commercial and clinical weight in this window. Taken together, the activity across June and July 2026 reflects both the breadth of the late-stage pipeline and the ongoing pressure on the FDA to deliver timely, evidence-based judgements in a period of institutional transition. What emerges from this busy regulatory window will have lasting implications for patients, pharma pipelines, and the credibility of the agency itself.
